Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 12,239 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares of the company’s stock, valued at approximately $1,294,312. The trade was a 7.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Aurinia Pharmaceuticals Trading Up 1.3 %

Shares of Aurinia Pharmaceuticals stock traded up $0.10 during trading on Tuesday, reaching $8.08. 3,640,172 shares of the company were exchanged, compared to its average volume of 1,449,999. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The business has a 50-day moving average price of $8.13 and a 200-day moving average price of $7.85. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22.

Analyst Ratings Changes

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Aurinia Pharmaceuticals by 21.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 363,674 shares of the biotechnology company’s stock valued at $3,266,000 after acquiring an additional 65,220 shares during the period. Woodline Partners LP lifted its holdings in shares of Aurinia Pharmaceuticals by 69.7% in the fourth quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company’s stock valued at $7,628,000 after purchasing an additional 348,983 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Tang Capital Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.